US10724067B2 - Thermochromic sensing devices, systems, and methods - Google Patents
Thermochromic sensing devices, systems, and methods Download PDFInfo
- Publication number
- US10724067B2 US10724067B2 US15/960,049 US201815960049A US10724067B2 US 10724067 B2 US10724067 B2 US 10724067B2 US 201815960049 A US201815960049 A US 201815960049A US 10724067 B2 US10724067 B2 US 10724067B2
- Authority
- US
- United States
- Prior art keywords
- test
- locations
- substances
- light
- live
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 42
- 238000012360 testing method Methods 0.000 claims abstract description 435
- 239000000126 substance Substances 0.000 claims abstract description 176
- 239000000463 material Substances 0.000 claims abstract description 153
- 230000003595 spectral effect Effects 0.000 claims abstract description 56
- 230000000694 effects Effects 0.000 claims abstract description 21
- 230000004044 response Effects 0.000 claims abstract description 16
- 230000007423 decrease Effects 0.000 claims abstract description 11
- 238000005259 measurement Methods 0.000 claims description 70
- 241000894006 Bacteria Species 0.000 claims description 63
- 230000012010 growth Effects 0.000 claims description 42
- 239000003814 drug Substances 0.000 claims description 28
- 230000003115 biocidal effect Effects 0.000 claims description 24
- 230000004060 metabolic process Effects 0.000 claims description 18
- 210000004027 cell Anatomy 0.000 claims description 16
- 239000003242 anti bacterial agent Substances 0.000 claims description 15
- 229940088710 antibiotic agent Drugs 0.000 claims description 14
- 238000012258 culturing Methods 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- 238000012544 monitoring process Methods 0.000 claims description 6
- 238000004113 cell culture Methods 0.000 claims description 4
- 241000233866 Fungi Species 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 210000004102 animal cell Anatomy 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims 3
- 244000005700 microbiome Species 0.000 claims 2
- 230000031070 response to heat Effects 0.000 claims 2
- 241000203069 Archaea Species 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 24
- 239000002609 medium Substances 0.000 description 42
- 239000010410 layer Substances 0.000 description 40
- 230000008859 change Effects 0.000 description 36
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 24
- 229940079593 drug Drugs 0.000 description 24
- 238000000576 coating method Methods 0.000 description 19
- 230000003287 optical effect Effects 0.000 description 19
- 238000001228 spectrum Methods 0.000 description 19
- 238000010586 diagram Methods 0.000 description 18
- 230000005540 biological transmission Effects 0.000 description 17
- 239000011248 coating agent Substances 0.000 description 15
- 230000008569 process Effects 0.000 description 14
- 238000009826 distribution Methods 0.000 description 13
- 239000000523 sample Substances 0.000 description 12
- 238000009640 blood culture Methods 0.000 description 11
- 239000013641 positive control Substances 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 238000007789 sealing Methods 0.000 description 9
- 238000013459 approach Methods 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- 239000004973 liquid crystal related substance Substances 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 239000000853 adhesive Substances 0.000 description 6
- 230000001070 adhesive effect Effects 0.000 description 6
- 230000000845 anti-microbial effect Effects 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 238000003794 Gram staining Methods 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000013610 patient sample Substances 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 239000004599 antimicrobial Substances 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- -1 e.g. Substances 0.000 description 4
- 238000000295 emission spectrum Methods 0.000 description 4
- 238000009413 insulation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 4
- MPPQGYCZBNURDG-UHFFFAOYSA-N 2-propionyl-6-dimethylaminonaphthalene Chemical compound C1=C(N(C)C)C=CC2=CC(C(=O)CC)=CC=C21 MPPQGYCZBNURDG-UHFFFAOYSA-N 0.000 description 3
- 238000009529 body temperature measurement Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 2
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- GPXJNWSHGFTCBW-UHFFFAOYSA-N Indium phosphide Chemical compound [In]#P GPXJNWSHGFTCBW-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920000297 Rayon Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229960000603 cefalotin Drugs 0.000 description 2
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229910021389 graphene Inorganic materials 0.000 description 2
- 229910002804 graphite Inorganic materials 0.000 description 2
- 239000010439 graphite Substances 0.000 description 2
- 239000003966 growth inhibitor Substances 0.000 description 2
- AMGQUBHHOARCQH-UHFFFAOYSA-N indium;oxotin Chemical compound [In].[Sn]=O AMGQUBHHOARCQH-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002964 rayon Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000004381 surface treatment Methods 0.000 description 2
- 230000002277 temperature effect Effects 0.000 description 2
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 2
- 229960004659 ticarcillin Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- LITBAYYWXZOHAW-XDZRHBBOSA-N (2s,5r,6r)-6-[[(2r)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2s,3s,5r)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]hept Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1.O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 LITBAYYWXZOHAW-XDZRHBBOSA-N 0.000 description 1
- SOVUOXKZCCAWOJ-HJYUBDRYSA-N (4s,4as,5ar,12ar)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O SOVUOXKZCCAWOJ-HJYUBDRYSA-N 0.000 description 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
- ZPLCXHWYPWVJDL-UHFFFAOYSA-N 4-[(4-hydroxyphenyl)methyl]-1,3-oxazolidin-2-one Chemical compound C1=CC(O)=CC=C1CC1NC(=O)OC1 ZPLCXHWYPWVJDL-UHFFFAOYSA-N 0.000 description 1
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 108010065152 Coagulase Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010013198 Daptomycin Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 101710185622 Pyrrolidone-carboxylate peptidase Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- 102100040653 Tryptophan 2,3-dioxygenase Human genes 0.000 description 1
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- FRHBOQMZUOWXQL-UHFFFAOYSA-L ammonium ferric citrate Chemical compound [NH4+].[Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FRHBOQMZUOWXQL-UHFFFAOYSA-L 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229940043312 ampicillin / sulbactam Drugs 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 208000037815 bloodstream infection Diseases 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- PPKJUHVNTMYXOD-PZGPJMECSA-N c49ws9n75l Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC2=CO1.N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O PPKJUHVNTMYXOD-PZGPJMECSA-N 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960002100 cefepime Drugs 0.000 description 1
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960003324 clavulanic acid Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229940047766 co-trimoxazole Drugs 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 102000030626 cysteine desulfurase Human genes 0.000 description 1
- 108091000099 cysteine desulfurase Proteins 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960005484 daptomycin Drugs 0.000 description 1
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 1
- 238000011157 data evaluation Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- NWOYIVRVSJDTLK-YSDBFZIDSA-L disodium;(2s,5r,6r)-6-[[(2r)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate;(1r,4s)-3,3-dimethyl-2,2,6-trioxo-2$l^{6}-thiabicyclo[3.2.0]heptane-4-carboxylate Chemical compound [Na+].[Na+].O=S1(=O)C(C)(C)[C@H](C([O-])=O)C2C(=O)C[C@H]21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 NWOYIVRVSJDTLK-YSDBFZIDSA-L 0.000 description 1
- 229960000895 doripenem Drugs 0.000 description 1
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960002770 ertapenem Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- XJRPTMORGOIMMI-UHFFFAOYSA-N ethyl 2-amino-4-(trifluoromethyl)-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C=1SC(N)=NC=1C(F)(F)F XJRPTMORGOIMMI-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229960004642 ferric ammonium citrate Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 238000013095 identification testing Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000004313 iron ammonium citrate Substances 0.000 description 1
- 235000000011 iron ammonium citrate Nutrition 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002346 layers by function Substances 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- CEQFOVLGLXCDCX-WUKNDPDISA-N methyl red Chemical compound C1=CC(N(C)C)=CC=C1\N=N\C1=CC=CC=C1C(O)=O CEQFOVLGLXCDCX-WUKNDPDISA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000003546 multiplexed readout Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229960000564 nitrofurantoin Drugs 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960002950 novobiocin Drugs 0.000 description 1
- YJQPYGGHQPGBLI-KGSXXDOSSA-N novobiocin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- SUWZHLCNFQWNPE-LATRNWQMSA-N optochin Chemical compound C([C@H]([C@H](C1)CC)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OCC)C=C21 SUWZHLCNFQWNPE-LATRNWQMSA-N 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 description 1
- 229940104641 piperacillin / tazobactam Drugs 0.000 description 1
- 229920000052 poly(p-xylylene) Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- DWHGNUUWCJZQHO-ZVDZYBSKSA-M potassium;(2s,5r,6r)-6-[[(2r)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2r,3z,5r)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 DWHGNUUWCJZQHO-ZVDZYBSKSA-M 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 108010071077 quinupristin-dalfopristin Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013643 reference control Substances 0.000 description 1
- 238000002310 reflectometry Methods 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 229940020707 synercid Drugs 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004089 tigecycline Drugs 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/508—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
- B01L3/5085—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above for multiple samples, e.g. microtitration plates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C12Q1/10—Enterobacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01K—MEASURING TEMPERATURE; MEASURING QUANTITY OF HEAT; THERMALLY-SENSITIVE ELEMENTS NOT OTHERWISE PROVIDED FOR
- G01K11/00—Measuring temperature based upon physical or chemical changes not covered by groups G01K3/00, G01K5/00, G01K7/00 or G01K9/00
- G01K11/12—Measuring temperature based upon physical or chemical changes not covered by groups G01K3/00, G01K5/00, G01K7/00 or G01K9/00 using changes in colour, translucency or reflectance
Definitions
- thermochromic sensing This disclosure relates generally devices for analyzing substances using thermochromic sensing and to related systems and methods.
- Susceptibility testing is performed to determine the effectiveness of a substance to inhibit the growth or cause the death of a live substance, e.g., bacteria, fungi, etc. In some cases, the goal of susceptibility testing is to predict the success or failure of antibiotic or other drug therapy. Tests are performed in a test vessel to determine the growth or lack thereof of a particular microbe to various drug types, drug combinations, and/or drug concentrations. Susceptibility testing is generally performed under controlled conditions and may be used to identify the most effective drug type, combination, and/or dosage to treat an infection caused by a particular type of bacteria, for example.
- Susceptibility testing for antibiotic testing can involve growing a secondary culture of bacteria from a primary culture obtained from a patient. Currently, culturing the bacteria involves many replication cycles before a measurable effect of the drug being tested can be detected. It is desirable to shorten the time required for susceptibility testing so that an appropriate therapy can be quickly delivered to a patient.
- a method includes culturing one or more live substances at a plurality of test locations of a test vessel.
- the test locations include a thermochromic material and one or more test substances.
- a spectral shift in light emanating from the thermochromic material of the test locations is detected.
- the spectral shift occurs in response to an increase or decrease in energy conversion by the live substance.
- An effect of the one or more test substances on the live substances is determined based on the detected spectral shift.
- Some embodiments are directed to a system comprising an incubation chamber including a compartment configured to receive a test vessel having one or more test substances, one or more live substances, and one or more thermochromic materials thermally coupled to the live substances disposed at one or more test locations.
- a measurement light source comprises one or more light emitters is configured to emit measurement light.
- a detector subsystem comprises one or more photosensing elements configured to sense light emanating from the thermochromic material in response to the measurement light. The detector subsystem provides an electrical signal that includes information about a spectrum of the light emanating from the thermochromic material. The spectrum of the emanating light indicates energy conversion of the one or more live substances that causes a change in temperature of the thermochromic materials.
- FIG. 1 is a plan view of a thermochromic sensing test vessel in accordance with some embodiments
- FIG. 2 is a cross sectional view of the test vessel of FIG. 1 .
- FIG. 3 is a cross sectional view of a test plate that includes a thermochromic material disposed in a layer that extends across the test plate in x and y directions near the bottoms of several test wells in accordance with some embodiments;
- FIG. 4 is a cross sectional view of a test vessel comprising a number of locations configured to contain a medium for culturing at least one live substance with thermochromic material disposed within the test medium in accordance with some embodiments;
- FIGS. 5 and 6 depict cross sectional diagrams of a test vessels that include locations that contain a medium suitable for culturing a live substance within an area on a relatively flat substrate in accordance with some embodiments;
- FIG. 7 is a flow diagram illustrating a process for making a thermochromic sensing test vessel in accordance with some embodiments
- FIG. 8 is a cross sectional view of a thermochromic sensing test vessel configured for identification of a live substance.
- FIG. 9A shows a block diagram of a thermochromic temperature sensing test system in accordance with some embodiments.
- FIG. 9B shows a diagram of a portion of a thermochromic temperature sensing test system that includes two color channels in accordance with some embodiments
- FIG. 10A conceptually illustrates a wavelength shift detector that can be used to determine the existence and/or amount of shift in the spectrum of light emanating from a thermochromic material in accordance with some embodiments
- FIG. 10B conceptually illustrates a wavelength shift detector that detects both reflected and transmitted light in accordance with some embodiments
- FIGS. 11A and 11B are flow diagrams illustrating a thermochromic testing process in accordance with some embodiments.
- FIGS. 12A and 12B are flow diagrams illustrating processes for thermo-optical antimicrobial susceptibility testing (TOAST) using thermochromic sensing in accordance with some embodiments;
- FIGS. 13A through 13C are flow diagrams illustrating processes for bacteria identification and thermo-optical antimicrobial susceptibility testing using thermochromic sensing in accordance with some embodiments;
- FIG. 14A shows graphs that illustrate the simulated change in temperature ⁇ T (K) with respect to time for a growing E. coli colony with no antibiotic and with a minimum inhibitory concentration of antibiotic over a the range of thermionic sensing using the wavelength shift detector discussed in FIG. 10A ;
- FIG. 14B shows a portion of the graphs of FIG. 14A corresponding to the first 20 minutes of colony growth and indicating the measurement resolution achievable using the wavelength shift detector discussed in FIG. 10A .
- Thermochromism is the change in color of a material based on temperature.
- the color change of thermochromic materials can be relatively discrete and abrupt, or can vary gradually over a temperature range. The spectral changes may be evident in light that is scattered, reflected, absorbed, and/or fluoresces from the thermochromic material.
- Thermochromic materials may be organic or inorganic substances and/or may be monomers or polymers. Of particular interest for the approaches of the present disclosure are thermochromic liquid crystals, which exhibit thermochromism based on light reflectance.
- thermochromic material to optically indicate temperature changes caused by energy conversion of a live substance.
- live substances that can be monitored using the thermochromic sensing techniques described herein include one or more of bacteria, archea, protists, fungi, plant cells, animal cells, viruses in appropriate host cells, phages in appropriate host cells, cancer cell cultures, and tissue cell cultures.
- the rate of energy conversion of the live substance can be related to the metabolism of the ensemble of live cells. In particular the number of cells increasing due to cell mitosis is a form of increase in ensemble metabolism.
- the metabolism of the individual cells combined comprises the ensemble metabolism. Metabolism often includes the oxidation of glucose or other carbohydrates to release energy and chemical byproducts. In this context metabolism is meant to be the mechanism through which chemical energy is converted into other forms of energy, including heat. Heat in turn can cause a temperature change of the substance or live matter that performs the metabolism. Temperature change of live matter will result in temperature change, normally a temperature increase, of the surrounding material including, cell culture medium, buffer material, vessel material and thermochromic material. The amount of heat transfer from one material to the next is dominated by material properties. Therefore, it is possible to control the heat transfer by material choice. It is desirable that the heat generated by metabolism is isolated from transfer into the vessel material and instead thermally connected or coupled to the thermochromic material.
- thermochromic sensing devices, systems, and methods disclosed herein can be used to detect and/or monitor growth of live substances and are particularly useful in determining the efficacy of various pharmaceutical agents, e.g., drug types, drug dosages, and drug combinations, such as anti-microbial, anti-viral, and/or anti-fungal drugs.
- a spectral shift can occur in any kind of emission, absorption, fluorescence, reflection, or transmission, or any other light spectrum.
- a spectral shift in a light spectrum can be described as the difference between centroids of two light spectra.
- the wavelength shift may be determined by determining a measured centroid position with an implicit centroid position, determined in for example a calibration measurement or a nominal centroid position.
- the wavelength shift may be determined by comparing two different centroids of two different spectra effectively simultaneously to perform a referenced wavelength shift measurement.
- Light spectra, or light intensity spectra may be measured in various measurement unit.
- the varying parameter of the spectrum i.e. Abscissa
- the photon energy often measured in wavelength.
- the wavelength shift can be measured in wavelength units, for example nanometers (nm).
- the peak wavelength is a good approximation of the centroid position or the difference of peak positions relative to one another is a good approximation of wavelength shift.
- the centroid determination may be influenced by measurement parameters that may vary over the wavelength shift detection range so that there are additional measurement factors that are contributing to centroid measurements, for example wavelength dependent sensitivity of detectors. These measurement influences can be considered as systematic errors of the measurements and are often compensated for by calibration. Any such error, even if it is not compensated for, should be considered as part of the centroid, wavelength or wavelength shift measurement.
- emission spectra may consist of for example two relatively discrete emission distributions with two emission maxima. The centroid of these combined emission spectra can still be calculated and measured, a wavelength shift can still be calculated for such a spectrum.
- two fluorescence emission spectra are used in such a way that one of the emission spectra changes the emission intensity with temperature then temperature changes result in a wavelength shift of the overall spectrum.
- FIG. 1 and FIG. 2 are plan and cross sectional views, respectively, of a thermochromic sensing test vessel 100 in accordance with some embodiments.
- the test vessel 100 which may be a substantially planar test plate, includes one or more locations 101 configured to contain a medium 140 for culturing at least one live substance 150 .
- the test locations may be test wells which are recessed locations on a test plate, for example.
- the test vessel 100 may be any type of vessel or structure configured to contain a medium
- the test vessel 100 is a MICROTITER test plate, such as a standard 24-well MICROTITER plate, a standard 96-well MICROTITER plate, a standard 384-well MICROTITER plate, or a standard 1536-well MICROTITER plate, etc.
- the test wells of the test plate provide the locations 101 configured to contain the medium for culturing the live substance 150 .
- Each test well has walls 101 a and a bottom 101 b to contain the medium 140 .
- the test vessel 100 may include a cover 102 that covers the test wells and/or seals the medium within the test wells.
- test vessel 100 may be any type of vessel or structure configured to contain a medium
- the test vessel 100 may maintain standard MICROTITER plate pitch distances for fluidic handling, such as a standard 24-well MICROTITER plate pitch distances, a standard 96-well MICROTITER plate pitch distances, a standard 384-well MICROTITER plate pitch distances, or a standard 1536-well MICROTITER plate pitch distances, etc.
- standard MICROTITER plate pitch distances for fluidic handling such as a standard 24-well MICROTITER plate pitch distances, a standard 96-well MICROTITER plate pitch distances, a standard 384-well MICROTITER plate pitch distances, or a standard 1536-well MICROTITER plate pitch distances, etc.
- This could for example mean that test vessels could be loaded with standard MICROTITER fluidic handling tools (e.g.
- multiplexed pipettes by using a compatible MICROTITER fluidic interface but the samples are afterwards routed into any other appropriate position that does not necessarily have to be compatible with the MICROTITER standard, for example a single row of test wells, for example 24, 96, 384, or 1536 wells.
- thermochromic material 110 is thermally coupled to the one or more test locations.
- the thermochromic material may be disposed at the test locations, e.g., in, on, and/or about the test wells 101 .
- the thermochromic material 110 is thermally coupled to the medium 140 and/or live substance 150 contained within the test locations.
- the thermochromic material 110 is configured and arranged so that it exhibits a spectral shift in light, e.g., scattered, reflected, or fluorescent light, from the thermochromic material 110 in response to a temperature change of the live substance 150 and/or medium 140 due to energy conversion by the live substance 150 .
- the thermochromic material 110 is positioned to be sufficiently close and thermally coupled to the live substance 150 so as to be sensitive to changes in temperature due to energy conversion of the live substance 150 .
- thermochromic material 190 is disposed near test locations, such that the thermochromic material 190 is thermally coupled to the surrounding environment of test wells 101 .
- the thermochromic material 190 is a coating of thermochromic material thermally coupled to the test locations, e.g., a thermochromic coating disposed at the bottom of the test wells.
- thermochromic material 191 is disposed on the test plate, in order to monitor a larger temperature range than the test wells.
- This temperature sensing region is not significantly influenced by the amount of energy conversion of the live substance in any of the test wells, rather it will track the temperature development of the test plate once the plate is moved into the incubator and the test plate temperature is approaching nominal temperature conditions. Additionally, proper incubator functioning can be tracked or controlled with this read out.
- a cover 102 may comprise a lid and/or seal, e.g., sealing film.
- sealing film is a breathable sterile membrane (e.g. Corning microplate sealing tape white Rayon (with acrylic) or Thermo Scientific Gas Permeable Adhesive Seals). This sealing film is placed directly on the test vessel 100 to provide a sterile barrier over which the cover 102 (for example, non-sterile plastic) can then be placed.
- Another embodiment uses a sterile non-breathable adhesive seal (e.g. E&K Scientific SealPlate Adhesive Microplate Seals) as the lid 102 that covers the vessel.
- a sterile non-breathable adhesive seal e.g. E&K Scientific SealPlate Adhesive Microplate Seals
- This type of film provides an air-tight seal and thus does not require another lid on top of the sealing film.
- the cover 102 can be used to provide a barrier to exclude O2. Filling the test locations with media and using an air-tight seal will enable growth of anaerobic bacteria.
- the thermochromic material 110 may be a coating of thermochromic material 110 disposed along the walls 101 a and/or bottom 101 b of each individual test well 101 .
- the thermochromic material may be a layer 111 , e.g., a continuous layer, that extends across the test plate in x and y directions near the bottoms 101 b of several test wells 101 as illustrated in the cross sectional view of FIG. 3 .
- the spectral shift in light emanating from the thermochromic material 110 (see FIG. 2 ), 111 (see FIG. 3 ), such as the spectral shift of the reflected, scattered, transmitted, and/or fluorescent light, can be detected using one or more optical detectors.
- the optical detectors may be located at any position relative to the test vessel where the light emanating from the thermochromic material is detectable. For example, in some embodiments, the detector may be positioned above, below, and/or along the walls 101 a of the test wells 101 .
- the reflected, scattered, transmitted, and/or fluorescent light emanating from the thermochromic material 110 is relayed onto the optical detector by appropriate optical components 180 such as lenses, objective lenses, lens combinations, imaging optics, plane-, concave-, convex-mirrors, fibers, gratings, prisms, and other elements.
- optical components 180 such as lenses, objective lenses, lens combinations, imaging optics, plane-, concave-, convex-mirrors, fibers, gratings, prisms, and other elements.
- the optical components may maintain image information or not.
- the reflected, scattered, transmitted, and/or fluorescent light emanating from the thermochromic material 110 derives from measurement light that is ambient light, e.g., from sunlight, room light, etc., which encounters the thermochromic material 110 , 111 and is scattered, transmitted, reflected or absorbed by the thermochromic material 110 , 111 .
- at least one light source 195 , 196 is used to emit and to direct the measurement light 195 a , 196 a toward the test wells 101 such that the measurement light 195 a , 196 a encounters the thermochromic material 110 , 111 .
- the thermochromic material 110 , 111 reflects a portion of the measurement light 195 a , 196 a .
- FIGS. 2 and 3 show reflected light 198 a , 199 a that can be detected by detectors 198 , 199 positioned above and/or below the bottom of the test wells 101 .
- the thermochromic material 110 , 111 absorbs a portion of the measurement light 195 a , 196 a , the absorption of the measurement light 195 a , 196 b causing the thermochromic material 110 , 111 to fluoresce.
- 2 and 3 indicate fluorescent light 198 b , 199 b that can be detected by one or more detectors 198 , 199 positioned above and/or below the test wells 101 .
- a portion of the measurement light 195 a , 196 a is scattered by the thermochromic material 110 , 111 .
- the scattered light 198 c , 199 c can be detected by one or more detectors 198 , 199 positioned above and/or below the test wells 101 .
- a portion of the measurement light 195 a , 196 a is transmitted by the thermochromic material 110 , 111 .
- the transmitted light 198 d , 199 d can be detected by one or more detectors 198 , 199 positioned above and/or below the test wells 101 .
- the measurement light may be transmitted to the thermochromic material by a waveguide, e.g., an optical fiber or polymer waveguide.
- the reflected, scattered, transmitted or fluorescent light emanating from the thermochromic material may be transmitted to the detector through a waveguide.
- the waveguides may be integrally formed in the test vessel for transmitting measurement light and/or light emanating from the thermochromic material.
- the reflected, scattered, transmitted or fluorescent light emanating from the thermochromic material may be transmitted to the detector through a lens that is integral to the well plate structure, for example formed during the injection molding of the test plate.
- At least a portion 100 a of the test plate 100 in the region of the test wells 101 is substantially optically transmissive at the wavelengths of the measurement light 196 a and/or at the wavelengths of the reflected 199 a , scattered 199 b , transmitted 199 d , and/or fluorescent light 198 c emanating from the thermochromic material 110 .
- substantially optically transmissive means that the transmittance of light at the wavelengths of the measurement light and/or the light emanating from the thermochromic material is greater than 50%.
- the reflected, scattered, transmitted or fluorescent light emanating from the thermochromic material may be transmitted to the detector through a flat transparent bottom, for example glass, polypropylene, polystyrene, polycarbonate or quartz.
- thermochromic materials can be used to optically indicate the temperature of the test vessels.
- Thermochromic materials can show a variety of optical effects such as temperature dependent fluorescence intensity or temperature dependent reflection or scattering spectra.
- thermochromic liquid crystals show very strong temperature dependent reflection spectra.
- thermochromic material used for thermochromic temperature sensing of the live substances may comprise any suitable type of thermochromic material such as thermochromic liquid crystals, leuco dyes, fluorophores, Prodan bound to DPPC, and/or a fluorescent proteins.
- thermochromic liquid crystals the spectral changes result from temperature-dependent intermolecular spacing. For example, monitoring a specific selected reflectance from a thermochromic liquid crystal surface has shown up to a 13,000% change in intensity per K in a ratiometric color measurement or a wavelength shift of hundreds of nm/K up to about 1000 nm/K.
- thermochromic material that could be optimized genetically/biologically for thermochromic temperature sensing, e.g., optimized for pharmaceutical susceptibility testing and/or other monitoring of the growth/decline of live substances.
- thermochromic temperature sensing can be further enhanced by comparing the response of two different types of thermochromic materials with differing temperature responses and monitoring the change in intensity ratio between the two emission peaks from the two thermochromic materials.
- the two thermochromic materials are chosen such that one material shows a temperature dependent fluorescence intensity change, and the other is either independent of temperature, or has a change that is opposite to the first material.
- thermochromic liquid crystal having a wavelength shift of about 1000 nm/K would exhibit a wavelength shift of about 10 picometer (pm) when subjected to a temperature change of about 10 ⁇ K due to energy conversion by a live substance.
- a 1.6 ⁇ 10 ⁇ 6 K ⁇ 1.6 ⁇ 10 ⁇ 5 K change in temperature due to energy conversion would result in a 1.6—16 picometer (pm) wavelength shift.
- the thermochromic material may be configured to exhibit a spectral shift in the fluorescence, reflectance, or scattering spectrum with temperature in a range of about 0.5 nm/K to about 1000 nm/K.
- one or more optional additional layers or coatings can be disposed along one or both major sides of the thermochromic material layer.
- the optional additional layers may extend along the bottom 101 b and/or walls 101 a of the test wells 101 .
- one or more optional additional layers 120 , 121 , 130 , 131 can be positioned between the thermochromic material coating 110 , 111 and the medium 140 and/or live substance 150 within each test well 101 , as shown in FIGS. 2 and 3 .
- at least one of the optional additional layers 130 may be a light absorbing layer.
- thermochromic material 110 , 111 and the medium 140 and/or live substance 150 can enhance sensitivity of the thermochromic sensing due to the absorbing properties of the layer. Light that is not reflected, scattered, absorbed by the thermochromic material coating 110 , 111 now does not contribute to the reflected, scattered or fluorescence light detection.
- the use of a light blocking layer may enhance the signal to noise ratio of thermochromic sensing by reducing the component of the detector signal produced by non-signal light detected by the detector, wherein non-signal light is light other than light emanating from the thermochromic material.
- At least one of the optional additional layers 130 , 121 may be a heat conducting layer.
- the use of a heat conducting layer positioned between the thermochromic material 110 , 111 and the medium 140 and/or live substance 150 can enhance sensitivity of the thermochromic sensing due to an improved heat conductivity from the medium 140 and/or live substance 150 to the thermochromic material coating 110 , 111 .
- Energy converted by the live substance 150 results in heat generation within the medium 140 and thereby in a temperature increase of the medium and/or live substance 150 .
- a temperature difference between the medium and the ambient surrounding will result in a temperature gradient in the transition zone.
- thermochromic material is part of the transition zone, it is beneficial if a heat conducting layer ensures the heat transfer from the medium to the thermochromic layer so that both ideally have the same temperature.
- the heat conducting layer may consist of indium tin oxide (ITO), metal, diamond, zinc oxide, graphene, graphite, and indium phosphide.
- At least one of the optional additional layers 131 , 120 may be a heat insulation layer.
- the use of a heat insulation layer positioned between the thermochromic material 110 , 111 and the base material of the test vessel structure can enhance sensitivity of the thermochromic sensing due to reduced heat conductivity from the thermochromic material 110 , 111 to the ambient equilibrium temperature. It is desirable to have the base material of the test vessel structure itself be made of low heat conductivity material.
- At least one of the optional additional layers 121 , 130 may be a sterile coating positioned to separate the thermochromic material 110 , 111 from the medium 140 .
- the thermochromic coating 110 , 111 may be disposed along the bottom surface of the test wells with the sterile biocompatible coating disposed over the thermochromic coating so that the thermochromic coating is between the bottom surface of the test well and the sterile coating.
- the sterile coating may comprise one or more of parylene, indium tin oxide (ITO), metal, polyethylene glycol (PEG), diamond, zinc oxide, graphene, graphite, and indium phosphide. Ideally these coatings are also biocompatible.
- FIG. 4 illustrates a test vessel 400 comprising a number of locations 401 configured to contain a medium 140 for culturing at least one live substance 150 .
- the thermochromic material e.g., thermochromic particles or regions 410 , are disposed within the test medium 140 as depicted in the cross sectional diagram of FIG. 4 .
- the spectral shift in light emanating from the thermochromic material 410 can be detected using one or more optical detectors.
- the optical detectors may be located at any position relative to the test vessel where the light emanating from the thermochromic material is detectable.
- the detector 198 , 199 may be positioned above and/or below the test wells 401 as illustrated in FIG. 4 .
- the reflected, scattered, transmitted, and/or fluorescent light emanating from the thermochromic material derives from measurement light that is ambient light, e.g., from sunlight, room light, etc., which encounters the thermochromic material 410 .
- at least one light source 195 , 196 is used to emit and to direct the measurement light 195 a , 196 a towards the test wells 401 such that the measurement light 195 a , 196 a encounters the thermochromic material 410 .
- a portion of the measurement light 195 a , 196 a is reflected by the thermochromic material 410 .
- the reflected light 198 a , 199 a can be detected by photo sensing elements 198 , 199 positioned above and/or below the bottom of the test wells 401 .
- thermochromic material 410 a portion of the measurement light 196 a , 196 a is absorbed by the thermochromic material 410 and causes the thermochromic material 410 to fluoresce.
- the fluorescent light 198 b , 199 b can be detected by one or more photo sensing elements 198 , 199 positioned above and/or below the test wells 401 .
- a portion of the measurement light 195 a , 196 a is scattered by the thermochromic material 410 .
- the scattered light 198 c , 199 c can be detected by one or more photo sensing elements 198 , 199 positioned above and/or below the test wells 401 .
- At least a portion 400 a of the test plate 400 in the region of the test wells 401 is substantially optically transmissive at the wavelengths of the measurement light 196 a and at the wavelengths of the reflected 199 a , scattered 199 b , and/or fluorescent light 198 c.
- one or more optional additional layers or coatings 420 can be disposed along the bottom of the test well 401 or elsewhere, e.g., along the walls 401 a of the test well 401 .
- the optional additional layers may extend both along the bottom 401 b and walls 401 a of the test wells 401 .
- at least one of the optional additional layers 420 may be a heat insulating layer. The heat insulating layer can be designed to enhance sensitivity of the thermochromic sensing due to the reduced heat transfer from the test location 401 to the sacrificial material of the test vessel 400 or the surrounding.
- At least one of the optional additional layers 420 may be a light blocking layer.
- the use of a light blocking layer may enhance the signal to noise ratio of thermochromic sensing by reducing the component of the detector signal produced by non-signal light, wherein non-signal light is light other than light emanating from the thermochromic material.
- FIGS. 5 and 6 depict cross sectional diagrams of a test vessel 500 , 600 that includes locations 501 , 601 configured to contain a medium 540 suitable for culturing one or more live substances 560 .
- medium 540 may be contained within an area on a relatively flat substrate 500 a .
- the locations 501 , 601 may be defined by surface treatments or coatings, 505 , e.g., a hydrophobic surface treatment configured to contain the medium within the locations 501 , 601 .
- the thermochromic material may be a layer 510 disposed on the substrate 500 a at the locations 501 .
- a cover 570 e.g., comprising a seal and/or lid.
- the test vessel is covered with a sealing film with or without an additional lid.
- Some embodiments use a protective lid with or without a seal.
- the cover 570 reduces heat loss due to evaporation and helps to maintain an appropriate environment within the test vessel 500 at the test locations 501 .
- mammalian cells are disposed at the test locations which need a certain head volume that contains the appropriate gas atmosphere, e.g., 5% CO2.
- anaerobic bacteria are disposed at the test locations and the cover provides a barrier that helps to exclude O2 which is toxic to these bacteria.
- filling the test locations with media and using an air-tight seal enables the growth of anaerobic bacteria.
- seal is a breathable sterile membrane (e.g. Corning microplate sealing tape white Rayon (with acrylic) or Thermo Scientific Gas Permeable Adhesive Seals). This sealing film is placed directly on the test vessel to provide a sterile barrier over which the lid (for example, non-sterile plastic) can then be placed.
- a breathable sterile membrane e.g. Corning microplate sealing tape white Rayon (with acrylic) or Thermo Scientific Gas Permeable Adhesive Seals.
- Another embodiment uses a sterile non-breathable adhesive seal (e.g. E&K Scientific SealPlate Adhesive Microplate Seals) to cover the vessel.
- a sterile non-breathable adhesive seal e.g. E&K Scientific SealPlate Adhesive Microplate Seals
- This type of film provides an air-tight seal and thus does not require another lid on top of the sealing film unless the lid is desired or needed for additional protection.
- the thermochromic material may be thermochromic regions 610 within the medium 540 , e.g., thermochromic particles embedded within the medium.
- the test vessel 500 , 600 may include one or more optional additional layers 520 , 530 , 620 disposed above and/or below the thermochromic material as discussed above.
- the additional optional layers 520 , 530 , 620 may comprise one or more of a heat absorbing layer, a light blocking layer and a sterile biocompatible layer.
- the test vessel includes a cover 570 , e.g. a seal and/or lid.
- FIG. 7 is a flow diagram illustrating a process for making a thermochromic sensing test vessel in accordance with some embodiments.
- the process includes providing 710 a test structure and disposing 720 a thermochromic material thermally coupled to test locations of the test structure.
- the thermochromic material may be disposed by coating the test wells of the standard test plate with one or more thermochromic materials.
- the bottom and/or walls of all of the test wells of a standard plate could be coated.
- the bottom and/or walls of some test wells may be coated with thermochromic material, whereas other test wells are left uncoated.
- the thermochromic material may be disposed at the test locations by placing thermochromic particles into a medium contained by the test wells and/or by placing a medium that contains thermochromic material within the test wells.
- additional functional material layers may be disposed 730 on the test structure, for example, heat conducting layers, light blocking layers, thermal insulation layers.
- the additional functional layers may be disposed before or after the thermochromic material is disposed at the test locations.
- Subsequently sterilizing the test structure 740 may be accomplished by one or more of the following methods: heat, chemicals, or irradiation.
- Heat sterilization may be achieved using either moist heat (steam) or dry heat.
- Chemicals may be used to sterilize heat-sensitive materials including many plastics. Either gases or liquids may be used. Gases used for chemical sterilization include ethylene oxide (EtO), nitrogen dioxide (NO 2 ) or ozone.
- Liquid chemical sterilization may be achieved using glutaraldehyde, formaldehyde, hydrogen peroxide (H 2 O 2 ), or peracetic acid.
- Radiation sterilization may be achieved using electron beams, X-rays, gamma rays, or irradiation by subatomic particles.
- the sterilized test structure is packaged and sealed in such ways that the content of the package remains sterile until the mechanical integrity of the package is compromised, either inadvertently or deliberately. Normal deliberate opening maintains a sterile test plate and allows filling the test vessels exclusively with the live matter from the intended sample.
- test substances e.g., a pharmaceutical, antimicrobial, antifungal substance
- Different locations of the test vessel e.g., test wells 101 of the test vessel 100
- This test set up can be used to monitor the effect of the different types, combinations, and concentrations of the test substance on a live substance.
- the type, combination, and/or concentration of the test substance 160 may be substantially the same at a number of the test locations, and the live substance may vary. This test set up can be used to test the effect of the same type, combination, and concentration of the test substance on different types of live substances.
- thermochromic sensing test vessel is used for pharmaceutical, e.g., antimicrobial susceptibility testing (AST).
- AST antimicrobial susceptibility testing
- the test substance 160 comprises one or more types of antibiotic and the test locations contain different types, different combinations, and/or different concentrations of antibiotic.
- antibiotics and combinations of antibiotics suitable for use in AST include, but are not limited to: Amikacin, Amoxicillin/Clavulanic Acid, Ampicillin, Ampicillin/Sulbactam, Azithromycin, Aztreonam, Cefalotin, Cefazolin, Cefepime, Cefoxitin, Ceftazidime, Ceftriaxone, Cefuroxime, Cephalothin, Chloramphenicol, Ciprofloxacin, Clarithromycin, Clindamycin, Daptomycin, Doripenem, Ertapenem, Erythromycin, Gatifloxacin, Gentamicin, Imipenem, Levofloxacin, Meropenem, Moxiflaxacin, Nalidixic Acid, Nitrofurantoin, Norfloxacin, Ofloxacin, Oxacillin, Penicillin, Piperacillin, Piperacillin/Tazobactam, Rifampin, Sulfamethoxazole
- thermochromic sensing test vessel 100 is used for identification of the live substance 150 .
- the test substance 860 comprises one or more types of substrates to measure carbon source utilization (e.g. mannitol, glucose, lactose, maltose, citrate, acetate, acetamide), enzymatic activity (e.g. catalase, oxidase, coagulase, pyrase, urease, decarboxylase, dihydrolase, phenylalanine deaminase, cysteine desulfurase (H2S production), tryptophanase (indole production)), or resistance (e.g.
- carbon source utilization e.g. mannitol, glucose, lactose, maltose, citrate, acetate, acetamide
- enzymatic activity e.g. catalase, oxidase, coagulase, pyrase, urease, decarboxylase,
- the growth medium may contain an indicator substance ( 861 ) in addition to the test substance 860 .
- indicator substances include, but are not limited to: bromothymol blue, ferric ammonium citrate, bromocresol purple, ferric chloride, ferrous sulfate, 4-Dimethylaminobenzaldehyde, and methyl red.
- the test substance 860 used for the identification of the live substance directly produces a fluorescent or chromogenic compound when incubated in the presence of the appropriate live substance 150 .
- the indicator substance 861 produces a fluorescent or chromogenic compound when the test substance 860 is incubated in the presence of the appropriate live substance 150 .
- the fluorescence or absorbance resulting from incubation of the live substance 150 in the presence of the test compound 860 can be measured using one or both of light sources 195 , 196 and using the detectors 198 , 199 and/or additional light sources and/or detectors positioned above or below the test locations.
- Combinations of enzyme substrates, growth promotors and growth inhibitors as measured by the TOAST mechanism or other optical means gives a metabolic or other biochemical profile that may be used for identification of live matter.
- the AST may be performed following isolation and identification of the live substance from a positive blood culture.
- the identification step may be performed a using the thermochromic sensing test vessel as described above.
- the live substance may be identified using another method such as standard growth and biochemical characteristics or rapid identification methods such as matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS).
- MALDI-TOF MS matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
- the AST may be initiated prior to identification of the live substance, relying on the Gram stain results of the positive blood culture to select the appropriate panel of test compounds to use in the AST.
- the test vessel can be designed as a one-use disposable component.
- the thermochromic sensing test vessel may be part of a kit that includes the sterile thermochromic sensing test vessel, e.g., as discussed in connection with FIGS. 1-6 .
- the thermochromic sensing test vessel of the kit can be pre-loaded with medium and test substance.
- the test substance comprises different types, amounts and/or combinations of pharmaceuticals or other agents that are preloaded at different test locations of a test vessel.
- the test laboratory receiving the kit would insert the live substance at the test locations, test of the efficacy of the types, amounts and/or combinations of the test substance preloaded at each of the test locations, and then dispose of the kit after the testing is complete.
- some of the test locations may be used as control locations, wherein the test substance and/or the live substance is not inserted at the control test locations.
- the test vessel may be configured to be removably inserted into a compartment of a system that facilitates automatic testing of test substances using thermochromic sensing.
- the test vessel may be configured as a cartridge with mechanical holding features that engage with compatible features of the compartment.
- FIG. 9A shows a block diagram of a thermochromic temperature sensing test system 900 in accordance with some embodiments.
- the test system 900 includes an incubator 905 configured to automatically control the ambient environment, e.g., light, temperature, humidity, gas composition, CO 2 concentration, etc. of the test vessel 902 and/or other components of the system during testing.
- Temperature compensation circuitry 930 may comprise a temperature sensor coupled to compensation circuitry configured to compensate for temperature effects and therefore spectral shift of the thermochromic material that are caused by factors other than energy conversion by the live substance. These temperature effects may be caused by room temperature fluctuation and they may be larger than the maximum temperature measurement range of the optical temperature measurement range used for individual test wells 101 . Therefore, the temperature of individual, groups of individual or all test wells can be adjusted with temperature compensation circuitry 930 .
- Temperature compensation circuitry 930 may contain heaters, coolers, resistive heaters, radiative heaters, heat exchangers, water supply, thermoelectric coolers, Peltier elements, evaporative coolers, temperature sensors, thermistors, thermo couplers and optical temperature read out sensors that are based on wavelength shift detection of thermochromic material (for example 191 and 190 ).
- the test vessel 902 includes fluidic channels 185 b (shown in FIG. 1 ) fluidically coupled to the test locations 101 so that a thermally equilibrated liquid, e.g., predominantly water based, potentially with the addition of disinfectant agents, from the host incubation and read-out system 900 can be connected to the test vessel 902 .
- the fluidic channels 185 b can allow a fluid to be introduced into heat exchange regions of the test vessel near the test locations and/or control locations. Mass flow of the thermally equilibrated liquid into the test vessel 902 will bring the device temperature, including the content of the test sites 101 to a thermal equilibrium in a faster and more stable way than for example heat exchange by circulating gas or purely radiative heat exchange.
- the test vessel 902 includes fluidic channels 185 a (shown in FIG. 1 ) that fluidically coupled to the test locations 101 so that the test substance can be filled into several or all test location through these fluidic channels.
- the test vessel 902 can be configured as a cartridge that may be removably inserted into a compartment 901 of the test system 900 .
- the test vessel 902 includes mechanical features 902 a , e.g., protrusions, which engage with mechanical features 901 a , e.g., slots, of the compartment to mechanically position and retain the test vessel 802 within the compartment 901 .
- the test vessel 902 can bear unique markings or identifiers that can be either read by humans, e.g. alphanumerical combinations, serial number or names, or by appropriate machines, e.g. bar codes or QR codes.
- the test vessel 902 can also be marked with alignment markings that define measurement test regions, for example a blue ring around each thermochromic material region 110 (see FIG. 2 ), 111 (see FIG. 3 ) for each test vessel 101 , lines forming a coordinate system, alignment crosses in several positions on the test vessel.
- the markings on the test vessel may indicate the regions of interest (ROI), i.e. the test locations 101 for automated readout.
- ROI regions of interest
- the markings may also imply the regions of interest by providing a coordinate system. The regions of interest would then be located at known, pre-defined coordinates.
- the system 900 can include a measurement light source 910 configured to generate and direct measurement light toward the test locations of the test vessel 902 .
- the light source 910 includes a light emitter, e.g., a light emitting diode (LED), a lamp, and/or laser, configured to emit the measurement light and components configured to cause the measurement light be directed to the test locations of the test vessel.
- the measurement light is optically multiplexed or directed to the multiple test locations by scanning the measurement light across the test locations of the test vessel, for example by scanning mirrors or rotating mirrors or mirror arrays (digital light processing) or by acousto-optical modulators or by phased array optics.
- the measurement light scanning may be implemented by directing the light produced by a stationary measurement light emitter across multiple test locations, e.g., using a lens and/or mirror array. In some embodiments, scanning the measurement light across the test locations may be implemented by physically moving the light source and test vessel relative to each other. In some embodiments, the measurement light may be directed to the test locations through an optical waveguide. In some embodiments, the measurement light may reach a subset of test regions of interest or the measurement light may reach all test regions simultaneously, for example by illuminating the total area of all thermochromic material regions of the test vessel.
- the measurement light may include two or more distinct measurement light sources or measurement light characteristics that are individually addressable.
- two or more individually switchable LEDs that exhibit a different spectral emission characteristic could serve as measurement light sources. These light sources could alternatingly probe the reflectivity of a thermochromic liquid crystal in different spectral regimes.
- a light intensity detector for example a monochrome camera, could then compare the intensity values of the reflected light spatially resolved for the light spectrum of the first LED and then for the light of the second LED.
- LEDs with very different spectral characteristics can be utilized with a monochrome light detector to measure wavelength shifts.
- a single broad light source e.g.
- RGB-cameras could be used that sequentially utilize light different filters (e.g. dielectric transmission filters, absorptive transmission filters), or camera systems could be used that use several image sensors and the incoming light is split by color selective elements such as dichroic mirrors as discussed below with reference to FIG. 9B .
- filters e.g. dielectric transmission filters, absorptive transmission filters
- camera systems could be used that use several image sensors and the incoming light is split by color selective elements such as dichroic mirrors as discussed below with reference to FIG. 9B .
- the system 900 includes detector subsystem 920 including one or more optical detectors configured to detect changes in the spectrum of light emanating from the thermochromic material of the test vessel, e.g., reflected, scattered, and/or fluorescent light.
- the sensors may comprise one or more of a photodiode, a phototransistor, photomultiplier tube, avalanche photo diode, a wavelength shift detector, an RGB camera, a hyperspectral camera, a spectrometer, a spectrograph, a dichroic mirror segmented image sensor, a Fourier spectrometer, and a dichroic mirror segmented sensor. In some embodiments there may be a one-to-one correspondence between the sensors and the test locations.
- the optical de-multiplexing may be accomplished by selectively directing the emanating light from each of the plurality of test locations to the sensor during different time periods. e.g., de-multiplexing using moveable mirrors for example scanning mirrors or rotating mirrors or mirror arrays (digital light processing) or by acousto-optical modulators or by phased array optics.
- the optical multiplexing may be accomplished by physically moving the sensors relative to the test vessel and/or physically moving the test vessel relative to the sensors.
- the output of the detector subsystem 920 can be provided to an processor 940 configured to detect, analyze, and/or monitor changes in the spectrum of the emanating light.
- the processor 940 may be configured to analyze results of the testing, and/or to generate reports of the testing results into a format that can be displayed, sent or in any way transmitted to a user, e.g., via a computerized user interface 950 .
- the processor 940 may send continuous updates to the user interface 950 as the testing is being performed wherein the user interface continuously updates its display, allowing a user to be quickly apprised of testing results.
- the processor 940 may be configured to generate an alert signal that is sent to the user interface 950 , wherein the user interface 950 produces an alert, e.g., an auditory and/or visual alert, based on the alert signal sent by the processor 940 .
- FIG. 9B illustrates a portion 960 of the thermochromic temperature sensing test system 900 in accordance with some embodiments.
- the portion of the system illustrated in FIG. 9B includes two color channels 971 , 972 that facilitate automatic testing of test substances according to some embodiments.
- a test vessel 962 comprising multiple test locations 962 a having thermochromic material disposed at the test locations 962 a is shown disposed within an incubator 961 .
- the incubator 961 controls the ambient environment of the test vessel 962 .
- Measurement light is provided to the system 960 by a measurement light source 965 e.g., comprising one or more light emitting devices that provide broad band measurement light.
- Imaging optics e.g., lenses 981 - 983
- Lens 981 images the light from the spatial region 962 b onto the dichroic mirror 970 .
- the dichroic mirror 970 separates the light into two different color channels 971 , 972 , each color channel associated with a camera 991 , 992 .
- Each color channel 971 , 972 provides an image 962 b - 1 , 962 b - 2 of substantially the same spatial region 962 b at different wavelengths.
- the dichroic mirror 970 has a center wavelength, ⁇ center , such that light having wavelengths greater than ⁇ center are directed toward camera 991 in a first color channel 971 and light having wavelengths less than ⁇ center are directed toward camera 992 in a second color channel 972 .
- the images 962 b - 1 , 962 b - 2 are not sufficiently identical, then translation, rotation or scaling transformations on the images 962 b - 1 , 962 b - 2 can be used to overlay the images so that they represent substantially the same spatial region 962 b .
- the images 962 b - 1 , 962 b - 2 usually contain one, several or all test locations 962 a and may include the thermochromic material disposed at the test locations 962 a .
- the images 962 b - 1 , 962 b - 2 include additional information such as markings. Additional markings may be identified by well-known techniques of computer vision and image processing and they may provide the system with operation parameters such as calibration data, patient data, mechanical alignment etc.
- the images 962 b - 1 , 962 b - 2 contain a representation of the different light intensities in the different wavelength regions for each image pixel.
- the light emanating from thermochromic material at the spatial region 962 b is included in the images 962 b - 1 , 962 b - 2 .
- it is possible to generate temperature maps of the imaged region by calculating the wavelength shift for each pixel in the color images 962 b - 1 , 962 b - 2 .
- Groups of pixel may be combined into a region of interest (ROI) in a given image.
- ROI region of interest
- the combination of pixels may for example be performed by the processor 940 by calculating the average intensity of pixel in the ROI, the sum intensity in the ROI, the median intensity in the ROI or any other mathematical operation based on the pixel values in the ROI to represent the intensity of the ROI.
- a ROI on the images substantially overlaps with a test location 962 a . More than one ROI can be defined in each image, in particular each test location 962 a in the image can be associated with at least one ROI.
- An ROI has at least two values associated with it. These two values represent the light intensities originating from the at least two color channels.
- a wavelength shift of an ROI may for example be calculated by subtracting the average values of the ROI in two color channels from another and dividing that value by the sum of the two ROI average values.
- a hyperspectral camera system is used to determine the wavelength shift of a ROI. In such a system, the peak intensity with respect to wavelength may be determined by finding the image of the wavelength region with the highest intensity in the ROI.
- the wavelength shift of an ROI may be calculated by omitting one of the three channels, for example the blue channel and treating the red and the green channels as the two channels described above. It may also be possible to add the red and green channel and treat this sum as a first color channel with the blue channel providing the second color channel as described above.
- the ROI can contain test locations 962 a and thermochromic material is thermally coupled to the test locations. Therefore the wavelength shift of a ROI can be related to the temperature in that ROI and thereby the temperature of the test locations of the test vessel.
- the camera system images all test locations and all positive and negative control locations in order to calculate the temperature development of the test locations over time and analyze it by comparing it to positive control location temperature developments over time.
- any of the above described system embodiments is suited to trace the temperature development of many locations on the test vessel by tracing local wavelength shifts on the vessel. Assuming that at least one thermochromic material is dispensed across the test plate at least in the relevant test locations and control locations, the local wavelength shift represents the local temperature on the plate.
- Ambient temperature changes will affect the wavelength shift of the whole test plate, independent of temperature changes in/on the individual test locations. These ambient temperature changes are not necessarily homogeneous across the test plate.
- the temperature change of a test location can be referenced by the temperature change of an adjacent control location that does not contain any test substance and thereby serves as a test location for common mode rejection of ambient temperature fluctuations. It is noteworthy that the control location may surround the test location or may have a different size or shape than the test location. In particular the control location may not contain any live substance and therefore this control location serves as a negative control location that traces ambient temperature changes. By subtracting the temperature of the negative control location from the temperature of the test location at each measurement point in time, the temperature change of the test location is traced through time, to first order independent of ambient temperature changes.
- a positive control location contains living substance without any drug that could inhibit the metabolism of the live substance and its colony growth.
- the system conditions such as nominal ambient temperature, ambient gas composition, etc. should be chosen to promote the growth of live substance.
- Positive control locations may be corrected for ambient temperature changes with readings from negative control locations in the same way that other test locations are corrected.
- FIG. 10A conceptually illustrates a wavelength shift detector 1000 that can be used as the detector subsystem 920 discussed in FIG. 9A to determine the center of a spectral distribution.
- the existence and/or amount of shift in spectrum of light for example emanating from the thermochromic material, can be determined by comparing two or more center of spectral light distributions.
- Light 1010 emanating from the thermochromic material and characterized by a central wavelength ⁇ i is input light to a spectrally varying optical transmission structure 1020 .
- the transmission structure 1020 has a laterally varying transmission function such that the transmission function varies as a function of position along a lateral axis 1099 of its exit surface 1020 a .
- the variation in transmission function can, for example, comprise a variation in intensity with wavelength according to a gradient, which can be a constant transmission gradient if it varies continuously and uniformly along the lateral axis 1099 .
- the variation in transmission function can be spike-like transmission gradient if the intensity varies with wavelength in a step-like manner along the lateral axis 1099 .
- light is described herein as transmitted with lateral variation when, in response to input light, transmitted light or output light varies with lateral position as a function of wavelength, and the variation with lateral position was not present in the input light. Variation with lateral position is illustrated in FIG. 10A by regions 1042 and 1044 .
- region 1042 of the transmission structure 1020 transmits a sub-band of light in a subrange centered about wavelength ⁇ a .
- region 1044 transmits a sub-band of light in a subrange centered about wavelength ⁇ b .
- the light from regions 1042 and 1044 represented respectively by rays 1046 and 1048 , is incident on the photosensing component 1060 at different positions.
- Light characterized by central wavelength ⁇ a is detected predominantly by the portion of the photosensing component 1060 at position 1062 .
- Light characterized by central wavelength ⁇ b is detected predominantly by the portion of the photosensing component 1060 at position 1064 .
- a change in the wavelength of the input light to ⁇ b will causes a change in the position of light exiting the transmission structure 1020 .
- This change in position will be indicated by a change in the light detected at positions 1062 and 1064 of the photosensing component 1060 .
- a difference between the intensity of incident light at wavelengths ⁇ a and ⁇ b can be indicated by a difference in light detected at positions 1062 and 1064 .
- a wavelength shift between wavelengths ⁇ a and ⁇ b or another change in wavelength distribution at the surface 1020 a of transmission structure 1020 can change relative quantities of photons provided at positions 1062 and 1064 , meaning that the quantities provided at the two positions have a different relation to each other after the change than they did before it.
- the quantities could increase or decrease, but by amounts such that the quantity at one position becomes a larger or smaller fraction of the quantity at the other position; the quantity at one position could change from being less than the quantity at the other position to being greater; or one quantity could increase while the other decreases; etc. All of these types of changes could occur over time.
- FIG. 10A shows the relationship between light intensity and position across the photosensing component 1060 in response to two different incident spectral patterns with light sub-bands having peak energy values.
- the first pattern with peak intensity at wavelength ⁇ a , results in a light spot on the photosensing component 1060 that has an intensity distribution represented by curve 1066 .
- the second distribution with a peak intensity at wavelength ⁇ b , similarly results in a light spot with an intensity distribution represented by curve 1068 .
- the first light spot represented by curve 1066
- the second light spot represented by curve 1068 , if a light narrow band of input light 1010 from the transmission structure 1020 makes a continuous transition from ⁇ a to ⁇ b .
- the graph also shows quantities of photons sensed by positions 1062 and 1064 in response to the first and second light spots.
- position 1062 of the photosensing component 1060 When the first spot is provided on photosensing component 1060 , position 1062 of the photosensing component 1060 generates a measurement quantity I 1 approximately proportional to the quantity of photons sensed by position 1062 , namely I a1 , and generates a measurement quantity I 2 approximately proportional to the quantity of photons sensed by position 1064 , namely I b1 .
- I 1 and I 2 can, for example, be photocurrents generated by a position sensitive photo detector.
- position 1062 senses a quantity proportional to I a2 and position 1064 senses a quantity proportional to I b2 .
- the relative quantities sensed by positions 1062 and 1064 change, with the first spot's relative quantity (I a1 /I b1 ) being greater than unity and the second spot's relative quantity (I a2 /I b2 ) being less than unity.
- the difference (I a1 ⁇ I b1 ) is a positive quantity whereas the difference (I a2 ⁇ I b2 ) is a negative quantity.
- the peak intensity position of each spot can be approximated by finding the position on the photosensing component having the highest sensed quantity.
- the intensity of adjacent or overlapping spectral regions is integrated and compared to determine a wavelength shift in the distribution.
- the photosensing component 1060 may comprise two detectors and the integration over spectral regions can be performed by measuring the two adjacent regions 1062 , 1064 using the two detectors, for example, photodiodes, split photodiodes, or photomultiplier tubes (PMT).
- PMT photomultiplier tubes
- the spectrally varying transmission structure 1020 can comprise linear variable filters or spectrally dispersive elements (e.g., prisms, grating, etc.).
- stacked or multi-anode PMTs can be used on a spectrograph. The measurements may be performed at a frequency of at least about 0.01 Hz, up to at least about 1 MHz or even more.
- the combination of a laterally varying transmission structure 1020 and the position-sensitive photosensing component 1060 may resolve wavelength shifts significantly smaller than 10 femtometer (fm) or even smaller than 5 fm, e.g., about 3 fm.
- the individual photodiodes of the photosensing component 1060 can generate photo currents I 1 and I 2 that are amplified with a transimpedance amplifier 1080 . Signal subtraction and addition may be performed with an analog circuit for superior noise performance prior to sampling by the analyzer. The center of the wavelength distribution can then be computed by ⁇ i ⁇ (I 1 ⁇ I 2 )/(I 1 +I 2 ). In some embodiments, the total size of the wavelength shift detector 1000 can closely approach that of the photosensing component 1060 , which is beneficial for mounting and long-term stability. Additional information involving the measurement of wavelength shifts in input light that can be used in conjunction with the thermochromic temperature sensing approaches disclosed herein is described in commonly owned U.S. Pat. No. 7,701,590 which is incorporated herein by reference.
- FIG. 10B illustrates another embodiment of a spectral detector 1070 .
- All wavelengths of light emanating 1071 from the thermochromic material (not shown in FIG. 10B ) in response to measurement light are directed through a dichroic mirror 1072 .
- Two different detectors, first detector 1081 and second detector 1082 are disposed to collect the transmitted and reflected light from the dichroic mirror 1072 .
- Detector 1081 may be used to measure the total light intensity contained in the wavelength region that is smaller than the mirror's center wavelength ⁇ center and detector 1082 may be used to measure the total light intensity contained in the wavelength region that is larger than the mirror's center wavelength ⁇ center .
- both measured light intensities would be identical (curve 1071 a ).
- detector 1082 would measure higher light intensities than detector 1081 . Therefore this detector used with the above-described method represents another way of detecting spectral light intensity distributions.
- additional optical elements 1075 may be introduced into the light detection path.
- additional bandpass filters in front of the detectors 1081 , 1082 may be used to limit the detected light to the spectral region that shows the largest shift for a given temperature change.
- additional optical elements 1075 may include imaging lenses. Imaging may be particularly interesting, when the light detectors are image detectors, such as cameras. The full area of the complete test vessel may be illuminated and the measurement light from numerous test sites may be sensed simultaneously in a scheme as presented in FIG. 10B , by imaging the test vessel onto at least two cameras. For two simultaneously taken images the color distribution and therefore the temperature of all test locations can now be measured by measuring the recorded intensity of the appropriate pixels for each test location on both cameras. Additional markings on the test vessel may be used to identify the test locations in the images.
- Thermochromic sensing may be used for a variety of testing protocols, such as testing the efficacy of various pharmaceuticals, e.g., antibiotics, antimicrobial agents, antifungal agents, cancer drugs, etc.
- the flow diagram of FIG. 11 illustrates a thermochromic testing process in accordance with some embodiments.
- the live substance is inserted 1101 into a medium disposed at test locations of a thermochromic test vessel.
- a test substance is also disposed in the medium.
- the live substance is thermally coupled to a thermochromic material located at the test locations.
- a spectral shift of light emanating from the thermochromic material is detected 1102 . The spectral shift occurs in response to a temperature change caused by energy conversion by the live substance.
- the amount and/or rate of energy converted by the live substance may be determined 1103 based on the spectral shift.
- live substance is a pathogen and the amount and/or rate of energy converted by the live substance indicates the susceptibility of the live substance to the test substance, e.g., an antibiotic.
- the live substance is a cell or tissue culture and the energy converted by the live substance can be related to mutations or other effects of the test substance on the cell or tissue culture.
- thermochromic sensing is particularly useful for antibiotic or antimicrobial susceptibility testing.
- the goals of antimicrobial susceptibility testing are to detect possible drug resistance in pathogens and to assure susceptibility of the pathogens to drugs of choice for particular infections.
- Antimicrobial susceptibility testing may provide quantitative results, e.g., minimum inhibitory concentration of the antimicrobial test substance, and/or may provide qualitative assessment of efficacy of the test substance with respect to the pathogen.
- New and emerging mechanisms of resistance exhibited by many bacteria require vigilance regarding the ability of AST to accurately detect resistance. Particularly in view of these emerging mechanisms of resistance, it seems likely that phenotypic measures of the level of susceptibility of bacterial isolates to antimicrobial agents will continue to be clinically relevant for years to come.
- AST measures the effect of drugs on the replication of microbes to determine which drug is best suited to kill the bacterium. AST may test many drugs in parallel in vitro to predict which drug works best in vivo. Thus, AST may test a broad sample of drugs so that the treatment choice can be targeted to the most effective antimicrobial drug for the particular bacteria.
- FIG. 11B is a flow diagram that illustrates a testing process in accordance with some embodiments.
- Test locations of a thermochromic sensing test vessel are filled with a sample 1112 .
- the sample may include one or more of a medium, a live substance, a substance to be tested, e.g., antibiotic, and, in some embodiments, a thermochromic material.
- the sample and other structures near the sample, e.g. test locations and control locations, are thermally equilibrated 1114 in an incubation chamber.
- One or more regions of the test vessel that include test locations and control locations are illuminated 1116 with measurement light. Images of the regions are detected 1118 by a camera system.
- multiple images of the regions are detected and alignment features of the images are registered 1120 to align the images.
- a transformation between the images is calculated based on the alignment.
- Regions of interest within the images are identified 1122 .
- the regions of interest may include test locations and/or positive and/or negative reference control locations.
- the light intensity 1124 and wavelength shift 1126 of the regions of interest in the images are determined.
- the temperatures for the regions of interest are determined 1128 , including determining the temperatures of the test locations and the positive and/or negative control locations.
- the process indicated by steps 1118 through 1128 is repeated until the conclusion of the test.
- the temperature changes in the region of interest are analyzed 1130 . Any significant findings based on the temperature changes are reported 1132 .
- registration of the alignment features and calculation of the transformation between images may be performed once and used for the test, rather than being performed during each measurement loop.
- thermochromic sensing approaches discussed herein use optical calorimetry to monitor the temperature of incubation vessels, e.g., incubation test wells, and thereby to determine the growth of pathogen cultures.
- the disclosed approaches can speed up AST by significantly increasing the detection sensitivity providing the ability to monitor bacterial growth (or its absence) in real time rather than by end-point measurements.
- use of the thermochromic sensing techniques described herein can reduce the time needed to obtain the minimum inhibitory concentration of antibiotic by more than 60%, more than 70% or even more than 80% when compared to current approaches.
- FIG. 12A is a flow diagram illustrating a process for thermo-optical antimicrobial susceptibility testing using thermochromic sensing in accordance with some embodiments.
- a blood culture instrument 1210
- an aliquot of the sample is subjected to Gram staining ( 1220 ) to identify the bacteria as Gram-negative or Gram-positive.
- the bacteria are introduced to test vessels for TOAST ( 1230 ).
- Bacteria is cultured 1240 in a medium at test locations of a test vessel, wherein different test locations contain different types, concentrations and/or combinations of antibiotic.
- a thermochromic material is disposed at the test locations and is thermally coupled to sense energy conversion of the bacteria.
- a spectral shift of the light emanating from the thermochromic material at each of the test locations is detected 1250 .
- the susceptibility of the bacteria to the different types, concentrations and/or combinations of antibiotic is determined 1260 based on the spectral shift.
- FIG. 12B is a flow diagram illustrating a process for using thermochromic sensing in accordance with some embodiments.
- a patient sample is flagged as positive for growth by a blood culture instrument ( 1210 b )
- Gram staining 1220 b
- the culture is subjected to identification testing ( 1230 b ) for example via standard biochemical tests or rapid mass spectrometry methods.
- identification testing 1230 b
- the bacteria are introduced to test vessels for TOAST ( 1240 b ).
- Bacteria are cultured 1250 b in a medium at test locations of a test vessel, wherein different test locations contain different types, concentrations and/or combinations of antibiotic.
- thermochromic material is disposed at the test locations and is thermally coupled to sense energy conversion of the bacteria.
- a spectral shift of the light emanating from the thermochromic material at each of the test locations is detected 1260 b .
- the susceptibility of the bacteria to the different types, concentrations and/or combinations of antibiotic is determined 1270 b based on the spectral shift.
- FIG. 13A is a flow diagram illustrating a process for bacteria identification and thermo-optical antimicrobial susceptibility testing using thermochromic sensing in accordance with some embodiments.
- a patient sample is flagged as positive for growth by a blood culture instrument ( 1310 )
- an aliquot of the sample is subjected to Gram staining ( 1320 ) to identify the bacteria as Gram-negative or Gram-positive.
- the bacteria are introduced to test vessels for identification ( 1330 ) and for TOAST ( 1350 ).
- bacteria is cultured 1335 in a medium at test locations of a test vessel, wherein different test locations contain different types, concentrations and/or combinations of test substance and indicator substance.
- thermochromic material is disposed at the test locations and is thermally coupled to sense energy conversion of the bacteria.
- a spectral shift of the light emanating from the thermochromic material at each of the test locations is detected 1370 .
- the identification of the bacteria is determined 1375 based on the spectral shift for example as explained in the description of FIG. 8 .
- the color change in the growth medium resulting from incubation of bacteria in the presence of the test substance and indicator substance is detected 1340 .
- the identification of the bacteria is determined 1345 based on the color change in the growth medium.
- bacteria are cultured 1355 in a medium at test locations of a test vessel, wherein different test locations contain different types, concentrations and/or combinations of antibiotic.
- thermochromic material is disposed at the test locations and is thermally coupled to sense energy conversion of the bacteria.
- a spectral shift of the light emanating from the thermochromic material at each of the test locations is detected 1360 .
- the susceptibility of the bacteria to the different types, concentrations and/or combinations of antibiotic is determined 1365 based on the spectral shift.
- FIG. 13B is a flow diagram illustrating a process for bacteria identification and thermo-optical antimicrobial susceptibility testing using thermochromic sensing in accordance with some embodiments.
- a patient sample is flagged as positive for growth by a blood culture instrument ( 1310 b )
- an aliquot of the sample is subjected to Gram staining ( 1320 b ) to identify the bacteria as Gram-negative or Gram-positive.
- Gram staining 1320 b
- the bacteria are introduced to test vessels for identification ( 1330 b ) and for antimicrobial susceptibility testing TOAST ( 1350 b ).
- bacteria are cultured 1335 b in a medium at test locations of a test vessel, wherein different test locations contain different types, concentrations and/or combinations of test substance and indicator substance.
- a thermochromic material is disposed at the test locations and is thermally coupled to sense energy conversion of the bacteria.
- a spectral shift of the light emanating from the thermochromic material at each of the test locations is detected 1340 b .
- the identification of the bacteria is determined 1345 b based on the spectral shift.
- bacteria are cultured 1355 b in a medium at test locations of a test vessel, wherein different test locations contain different types, concentrations and/or combinations of antibiotic.
- a thermochromic material is disposed at the test locations and is thermally coupled to sense energy conversion of the bacteria.
- a spectral shift of the light emanating from the thermochromic material at each of the test locations is detected 1360 b .
- the susceptibility of the bacteria to the different types, concentrations and/or combinations of antibiotic is determined 1365 b based on the spectral shift.
- FIG. 13C is a flow diagram illustrating a process for bacteria identification and thermo-optical antimicrobial susceptibility testing using thermochromic sensing in accordance with some embodiments.
- a patient sample is flagged as positive for growth by a blood culture instrument ( 1310 c )
- an aliquot of the sample is subjected to Gram staining ( 1320 c ) to identify the bacteria as Gram-negative or Gram-positive.
- the bacteria are introduced to test vessels for identification ( 1330 c ) and for TOAST ( 1350 c ).
- bacteria are cultured 1335 c in a medium at test locations of a test vessel, wherein different test locations contain different types, concentrations and/or combinations of test substance and indicator substance.
- the color change in the growth medium resulting from incubation of bacteria in the presence of the test substance and indicator substance is detected 1340 c .
- the identification of the bacteria is determined 1345 c based on the color change in the growth medium.
- bacteria are cultured 1355 c in a medium at test locations of a test vessel, wherein different test locations contain different types, concentrations and/or combinations of antibiotic.
- a thermochromic material is disposed at the test locations and is thermally coupled to sense energy conversion of the bacteria.
- a spectral shift of the light emanating from the thermochromic material at each of the test locations is detected 1360 c .
- the susceptibility of the bacteria to the different types, concentrations and/or combinations of antibiotic is determined 1365 c based on the spectral shift.
- thermochromic sensing using the thermochromic sensing test vessel described in connection test vessels and/or wavelength shift detectors described herein can resolve changes in wavelength of ⁇ 3 fm at a sampling rate of about 100 Hz which provides a resolution for temperature change of about 60 nanoKelvin (nK).
- FIG. 14A shows graphs that illustrate the change in temperature ⁇ T (K) with respect to time for a growing E. coli colony with no antibiotic (graph 1401 ) and with a minimum inhibitory concentration (MIC) of antibiotic (graph 1402 ) over a the range of 1 mK (about 290 minutes) of thermochromic sensing using the wavelength shift detectors discussed herein.
- the total test volume is assumed to be 0.1 ml and the initial bacteria concentration is assumed to be 500000 colony forming units per ml (cfu/ml).
- FIG. 14B shows a portion of the graphs 1401 , 1402 corresponding to the first 20 minutes of colony growth.
- the gridlines along the ⁇ T axis of FIG. 14B indicate the 60 nK resolution of the wavelength shift detector.
- Test sites with inhibited and uninhibited growth of live substance can therefore be identified by their differential temperature development over time. Test wells with live substance but without growth inhibitors will therefore serve as positive control sites in some embodiments.
- different test sites with different antimicrobial drugs may show effects of the drug at different times. One drug may act faster on the microbes than a second drug, although both drugs may be effective in inhibiting the bacterium colony of interest. Therefore, a continuous reporting of temperatures at different test sites may inform about the efficacy of a particular drug earlier than about the efficacy of a second drug or the efficacy of a second concentration of the first drug.
- a continuous reporting of differential temperature of test sites may serve a continuous representation of cell viability at that test site.
- a reporting system can continuously update any user for example about the currently best performing test substance.
- a physician could be informed by a TOAST system in an automated manner, for example by email or text message, that the first effective drug for a particular patient has been identified, if the energy conversion in the corresponding well has been continuously low for a prolonged time.
- ambient temperature even within the temperature controlled environment of an incubator, may drift significantly compared to the temperature increase of the test site.
- negative control sites or wells without live substance will be used to assess the ambient temperature drift.
- test locations are monitored over time. After initial insertion of the test plate into the full incubation and read-out system it is expected that temperatures will fluctuate strongly and that initial temperature reading will be ignored. After sufficient temperature stabilization, positive control locations show temperature changes for example as the ones shown in 1401 . Test locations with test substances that effectively inhibit growth of the live substance show temperature developments as depicted in 1402 . Test substances that not only inhibit the growth but produce cytotoxic or germicidal effects so that necrosis or apoptosis or any other form of death or reduction in metabolism of the live substance is induced will result in a temperature decrease of the test location compared with the positive control location.
- the temperature change over time will generally fall between the ones of positive control locations and negative control locations.
- Several metrics for determining the response of the live matter to the test substance can be used.
- the absolute value of temperature difference between a positive control location and a test location remains below a certain threshold value, for example 10 ⁇ K, during the course of the experimental duration to determine uninhibited growth of the test substance at a test location.
- the same thresholding calculation could be performed by averaging the temperature of several positive control locations.
- Another example for a metric of inhibited or uninhibited growth may be a temperature difference that is normalized by the absolute temperature of control locations.
- Another example for a metric may be the consideration of the temperature derivatives with respect to time.
- Another example for evaluation procedures may be a curve fit, for example an exponential growth fit to the temperature-time development data. Individual fit parameters for control and test location may then be used for evaluating the growth or the lack thereof of live substance in test locations. It will be appreciated that these are merely examples of possible data evaluation concepts that can be used in order to extract meaningful information from the fundamental data generated in a TOAST system. Depending on the live matter and the actual intent of a particular test these concepts or others may be utilized.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Clinical Laboratory Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
Description
Claims (15)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/960,049 US10724067B2 (en) | 2015-12-30 | 2018-04-23 | Thermochromic sensing devices, systems, and methods |
US16/939,738 US11718867B2 (en) | 2015-12-30 | 2020-07-27 | Thermochromic sensing devices, systems, and methods |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/984,739 US9963732B2 (en) | 2015-12-30 | 2015-12-30 | Thermochromic sensing devices, systems, and methods |
US15/960,049 US10724067B2 (en) | 2015-12-30 | 2018-04-23 | Thermochromic sensing devices, systems, and methods |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/984,739 Division US9963732B2 (en) | 2015-12-30 | 2015-12-30 | Thermochromic sensing devices, systems, and methods |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/939,738 Continuation US11718867B2 (en) | 2015-12-30 | 2020-07-27 | Thermochromic sensing devices, systems, and methods |
Publications (2)
Publication Number | Publication Date |
---|---|
US20180237820A1 US20180237820A1 (en) | 2018-08-23 |
US10724067B2 true US10724067B2 (en) | 2020-07-28 |
Family
ID=57860609
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/984,739 Active US9963732B2 (en) | 2015-12-30 | 2015-12-30 | Thermochromic sensing devices, systems, and methods |
US15/960,049 Active US10724067B2 (en) | 2015-12-30 | 2018-04-23 | Thermochromic sensing devices, systems, and methods |
US16/939,738 Active 2036-12-30 US11718867B2 (en) | 2015-12-30 | 2020-07-27 | Thermochromic sensing devices, systems, and methods |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/984,739 Active US9963732B2 (en) | 2015-12-30 | 2015-12-30 | Thermochromic sensing devices, systems, and methods |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/939,738 Active 2036-12-30 US11718867B2 (en) | 2015-12-30 | 2020-07-27 | Thermochromic sensing devices, systems, and methods |
Country Status (3)
Country | Link |
---|---|
US (3) | US9963732B2 (en) |
EP (1) | EP3187594B1 (en) |
JP (1) | JP6761751B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230046089A1 (en) * | 2021-08-13 | 2023-02-16 | Palo Alto Research Center Incorporated | Method and system for measuring the temperature of a thermochromic liquid crystal |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10378970B2 (en) | 2015-02-24 | 2019-08-13 | Prasidiux, Llc | Thermochromic liquid crystal temperature indicator |
US20170191020A1 (en) | 2015-12-30 | 2017-07-06 | Palo Alto Research Center Incorporated | Thermochromic sensing devices, systems, and methods |
US10598554B2 (en) | 2015-12-30 | 2020-03-24 | Palo Alto Research Center Incorporated | Thermochromic sensing for nanocalorimetry |
US9963732B2 (en) | 2015-12-30 | 2018-05-08 | Palo Alto Research Center Incorporated | Thermochromic sensing devices, systems, and methods |
US10842384B2 (en) * | 2017-01-12 | 2020-11-24 | Board Of Regents, The University Of Texas System | Thermochromic optical waveguide temperature sensors |
DE202017105967U1 (en) * | 2017-09-29 | 2018-01-31 | Airbus Operations Gmbh | Color-based heating system |
CA3118153A1 (en) * | 2018-11-16 | 2020-05-22 | SeLux Diagnostics, Inc. | System, method and interface for parallel processing of antimicrobial susceptibility tests using different samples |
US20210181547A1 (en) * | 2019-02-12 | 2021-06-17 | Sense Photonics, Inc. | Methods and systems for thermal control of an optical source or optical filter in a light detection and ranging (lidar) apparatus |
US11099083B2 (en) * | 2019-03-14 | 2021-08-24 | Kidde Technologies, Inc. | Aircraft overheat detection through fiber optic monitoring of light reflectance changing temperature strips |
JP2024517379A (en) | 2021-04-09 | 2024-04-22 | ラム フォトニクス インダストリアル エルエルシー | Method and system for laser optical sensing and profiling - Patents.com |
US11876484B2 (en) * | 2021-08-18 | 2024-01-16 | Renewable Energy Products Manufacturing Corp. | Protecting solar panels from damage due to overheating |
Citations (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3561269A (en) | 1969-12-15 | 1971-02-09 | Thermochromatic Systems Inc | Thermochromic temperature indication |
US3813554A (en) | 1972-12-12 | 1974-05-28 | Ibm | Addressable photochromic memory display device |
WO2000024438A1 (en) | 1998-10-27 | 2000-05-04 | Baylor College Of Medicine | Microbial activity indicator composition and coating |
US6160617A (en) | 1995-11-22 | 2000-12-12 | Kairos Scientific, Inc. | High resolution imaging microscope (HIRIM) and uses thereof |
US6265182B1 (en) | 1997-05-02 | 2001-07-24 | Zuhtu T. Kocagoz | Antibacterial susceptibility test |
US20020047003A1 (en) | 2000-06-28 | 2002-04-25 | William Bedingham | Enhanced sample processing devices, systems and methods |
US20030052305A1 (en) | 1999-09-03 | 2003-03-20 | Merck Patent Gmbh | Thermochromic liquid crystalline medium |
EP1630532A1 (en) | 2004-08-23 | 2006-03-01 | Palo Alto Research Center Incorporated | Wavelength detector |
US20060132542A1 (en) | 2004-12-21 | 2006-06-22 | Palo Alto Research Center Incorporated | Apparatus and method for improved electrostatic drop merging and mixing |
US7094595B2 (en) | 2000-10-30 | 2006-08-22 | Sru Biosystems, Inc. | Label-free high-throughput optical technique for detecting biomolecular interactions |
US20070009968A1 (en) | 2005-07-08 | 2007-01-11 | The Board Of Trustees Of The University Of Illinois | Photonic crystal biosensor structure and fabrication method |
US20070147473A1 (en) | 2005-12-27 | 2007-06-28 | Palo Alto Research Center Incorporated | Producing layered structures using printing |
US20070259598A1 (en) | 2003-09-17 | 2007-11-08 | Ribi Hans O | Plural Element Composite Materials, Methods for Making and Using the Same |
WO2008041146A2 (en) | 2006-10-05 | 2008-04-10 | Kimberly-Clark Worldwide, Inc. | Decontamination of filtration media for respiration |
US20080278722A1 (en) | 2007-05-07 | 2008-11-13 | The Board Of Trustees Of The University Of Illinois | Fluorescence detection enhancement using photonic crystal extraction |
US20090214804A1 (en) | 2005-11-23 | 2009-08-27 | Robert Levine | Thermal electric images |
US20090255535A1 (en) | 2006-01-25 | 2009-10-15 | Kanzer Steve H | Droplet collection devices and methods to detect and control airborne communicable diseases utilizing rfid |
US20090318306A1 (en) | 2008-06-23 | 2009-12-24 | Canon U.S. Life Sciences, Inc. | System and method for temperature referencing for melt curve data collection |
US7709047B2 (en) | 2003-01-24 | 2010-05-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target activated microtransfer |
US20100159610A1 (en) | 2008-12-18 | 2010-06-24 | Bayer Healthcare Llc | Method and assembly for determining the temperature of a test sensor |
US20100268112A1 (en) | 2009-04-21 | 2010-10-21 | Short Dan C | Thermocromatic patch for monitoring/detecting body temperature |
US7833800B2 (en) | 2002-04-01 | 2010-11-16 | Palo Alto Research Center Incorporated | Thermal sensing with bridge circuitry |
WO2012094426A2 (en) | 2011-01-04 | 2012-07-12 | Schwartz Alan N | Gel-based seals and fixation devices and associated systems and methods |
US20120312822A1 (en) | 2010-12-13 | 2012-12-13 | Meyer Intellectual Properties Limited | Cookware with Thermal Indicator |
US20130157376A1 (en) | 2011-12-20 | 2013-06-20 | Idaho Technology, Inc. | Thermal Cycler Calibration Device and Related Methods |
US20130225441A1 (en) | 2006-08-24 | 2013-08-29 | California Institute Of Technology | Integrated semiconductor bioarray |
US20130266977A1 (en) * | 2010-02-16 | 2013-10-10 | President And Fellows Of Harvard College | Methods and systems for detection of microbes |
US8594470B2 (en) | 2005-12-22 | 2013-11-26 | Palo Alto Research Center Incorporated | Transmittting light with lateral variation |
US8617899B2 (en) | 2008-02-14 | 2013-12-31 | Palo Alto Research Center Incorporated | Enhanced drop mixing using magnetic actuation |
US20140273191A1 (en) | 2013-03-15 | 2014-09-18 | New Renaissance Institute | Cell Incubator and Cellular Culture Laboratory Test bed |
US20140288381A1 (en) | 2005-03-09 | 2014-09-25 | Cutisense A/S | Three-dimensional adhesive device having a microelectronic system embedded therein |
US20170191881A1 (en) | 2015-12-30 | 2017-07-06 | Palo Alto Research Center Incorporated | Thermochromic sensing for nanocalorimetry |
US20170191020A1 (en) | 2015-12-30 | 2017-07-06 | Palo Alto Research Center Incorporated | Thermochromic sensing devices, systems, and methods |
US9963732B2 (en) | 2015-12-30 | 2018-05-08 | Palo Alto Research Center Incorporated | Thermochromic sensing devices, systems, and methods |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6660484B2 (en) | 1992-11-13 | 2003-12-09 | Regents Of The University Of California | Colorimetric glycopolythiophene biosensors |
US20090025535A1 (en) | 2007-07-23 | 2009-01-29 | Ian Montgomery | System and method for representing musical notes in an octave to the visible light spectrum and method therefor |
US8393785B2 (en) | 2009-05-14 | 2013-03-12 | Palo Alto Research Center Incorporated | Nanocalorimeter based on thermal probes |
JP6167873B2 (en) | 2013-06-27 | 2017-07-26 | ソニー株式会社 | Electronic device and control method of electronic device |
-
2015
- 2015-12-30 US US14/984,739 patent/US9963732B2/en active Active
-
2016
- 2016-12-15 EP EP16204547.0A patent/EP3187594B1/en active Active
- 2016-12-21 JP JP2016247361A patent/JP6761751B2/en active Active
-
2018
- 2018-04-23 US US15/960,049 patent/US10724067B2/en active Active
-
2020
- 2020-07-27 US US16/939,738 patent/US11718867B2/en active Active
Patent Citations (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3561269A (en) | 1969-12-15 | 1971-02-09 | Thermochromatic Systems Inc | Thermochromic temperature indication |
US3813554A (en) | 1972-12-12 | 1974-05-28 | Ibm | Addressable photochromic memory display device |
US6160617A (en) | 1995-11-22 | 2000-12-12 | Kairos Scientific, Inc. | High resolution imaging microscope (HIRIM) and uses thereof |
US6265182B1 (en) | 1997-05-02 | 2001-07-24 | Zuhtu T. Kocagoz | Antibacterial susceptibility test |
WO2000024438A1 (en) | 1998-10-27 | 2000-05-04 | Baylor College Of Medicine | Microbial activity indicator composition and coating |
US20030052305A1 (en) | 1999-09-03 | 2003-03-20 | Merck Patent Gmbh | Thermochromic liquid crystalline medium |
US20020047003A1 (en) | 2000-06-28 | 2002-04-25 | William Bedingham | Enhanced sample processing devices, systems and methods |
US7094595B2 (en) | 2000-10-30 | 2006-08-22 | Sru Biosystems, Inc. | Label-free high-throughput optical technique for detecting biomolecular interactions |
US7118710B2 (en) | 2000-10-30 | 2006-10-10 | Sru Biosystems, Inc. | Label-free high-throughput optical technique for detecting biomolecular interactions |
US7833800B2 (en) | 2002-04-01 | 2010-11-16 | Palo Alto Research Center Incorporated | Thermal sensing with bridge circuitry |
US7709047B2 (en) | 2003-01-24 | 2010-05-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target activated microtransfer |
US20070259598A1 (en) | 2003-09-17 | 2007-11-08 | Ribi Hans O | Plural Element Composite Materials, Methods for Making and Using the Same |
EP1630532A1 (en) | 2004-08-23 | 2006-03-01 | Palo Alto Research Center Incorporated | Wavelength detector |
US7701590B2 (en) | 2004-08-23 | 2010-04-20 | Palo Alto Research Center Incorporated | Apparatus, methods, devices, and systems in which differences and/or changes in photosensed positions and/or quantities relate to shifts and/or differences in photon energies |
US20060132542A1 (en) | 2004-12-21 | 2006-06-22 | Palo Alto Research Center Incorporated | Apparatus and method for improved electrostatic drop merging and mixing |
US8685216B2 (en) | 2004-12-21 | 2014-04-01 | Palo Alto Research Center Incorporated | Apparatus and method for improved electrostatic drop merging and mixing |
US20140288381A1 (en) | 2005-03-09 | 2014-09-25 | Cutisense A/S | Three-dimensional adhesive device having a microelectronic system embedded therein |
US20070009968A1 (en) | 2005-07-08 | 2007-01-11 | The Board Of Trustees Of The University Of Illinois | Photonic crystal biosensor structure and fabrication method |
US20090214804A1 (en) | 2005-11-23 | 2009-08-27 | Robert Levine | Thermal electric images |
US8594470B2 (en) | 2005-12-22 | 2013-11-26 | Palo Alto Research Center Incorporated | Transmittting light with lateral variation |
US7784173B2 (en) | 2005-12-27 | 2010-08-31 | Palo Alto Research Center Incorporated | Producing layered structures using printing |
US20070147473A1 (en) | 2005-12-27 | 2007-06-28 | Palo Alto Research Center Incorporated | Producing layered structures using printing |
US20090255535A1 (en) | 2006-01-25 | 2009-10-15 | Kanzer Steve H | Droplet collection devices and methods to detect and control airborne communicable diseases utilizing rfid |
US20130225441A1 (en) | 2006-08-24 | 2013-08-29 | California Institute Of Technology | Integrated semiconductor bioarray |
WO2008041146A2 (en) | 2006-10-05 | 2008-04-10 | Kimberly-Clark Worldwide, Inc. | Decontamination of filtration media for respiration |
US20080278722A1 (en) | 2007-05-07 | 2008-11-13 | The Board Of Trustees Of The University Of Illinois | Fluorescence detection enhancement using photonic crystal extraction |
US7768640B2 (en) | 2007-05-07 | 2010-08-03 | The Board Of Trustees Of The University Of Illinois | Fluorescence detection enhancement using photonic crystal extraction |
US8617899B2 (en) | 2008-02-14 | 2013-12-31 | Palo Alto Research Center Incorporated | Enhanced drop mixing using magnetic actuation |
US20090318306A1 (en) | 2008-06-23 | 2009-12-24 | Canon U.S. Life Sciences, Inc. | System and method for temperature referencing for melt curve data collection |
US20100159610A1 (en) | 2008-12-18 | 2010-06-24 | Bayer Healthcare Llc | Method and assembly for determining the temperature of a test sensor |
US20100268112A1 (en) | 2009-04-21 | 2010-10-21 | Short Dan C | Thermocromatic patch for monitoring/detecting body temperature |
US20130266977A1 (en) * | 2010-02-16 | 2013-10-10 | President And Fellows Of Harvard College | Methods and systems for detection of microbes |
US20120312822A1 (en) | 2010-12-13 | 2012-12-13 | Meyer Intellectual Properties Limited | Cookware with Thermal Indicator |
WO2012094426A2 (en) | 2011-01-04 | 2012-07-12 | Schwartz Alan N | Gel-based seals and fixation devices and associated systems and methods |
US20130157376A1 (en) | 2011-12-20 | 2013-06-20 | Idaho Technology, Inc. | Thermal Cycler Calibration Device and Related Methods |
US20140273191A1 (en) | 2013-03-15 | 2014-09-18 | New Renaissance Institute | Cell Incubator and Cellular Culture Laboratory Test bed |
US20170191881A1 (en) | 2015-12-30 | 2017-07-06 | Palo Alto Research Center Incorporated | Thermochromic sensing for nanocalorimetry |
US20170191020A1 (en) | 2015-12-30 | 2017-07-06 | Palo Alto Research Center Incorporated | Thermochromic sensing devices, systems, and methods |
US9963732B2 (en) | 2015-12-30 | 2018-05-08 | Palo Alto Research Center Incorporated | Thermochromic sensing devices, systems, and methods |
Non-Patent Citations (4)
Title |
---|
Dybko et al., "Thermochromic compounds as transducers for fibre optic temperature probes", Opt. Eng. 42(3), 656-661, Mar. 1, 2003. |
File History for U.S. Appl. No. 14/984,719 as retrieved from the U.S. Patent and Trademark Office on Apr. 22, 2019, 165 pages. |
File History for U.S. Appl. No. 14/984,739 as retrieved from the U.S. Patent and Trademark Office on Apr. 23, 2018, 261 pages. |
File History for U.S. Appl. No. 14/984,754 as retrieved from the U.S. Patent and Trademark Office on Jan. 15, 2019, 141 pages. |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230046089A1 (en) * | 2021-08-13 | 2023-02-16 | Palo Alto Research Center Incorporated | Method and system for measuring the temperature of a thermochromic liquid crystal |
US12044580B2 (en) * | 2021-08-13 | 2024-07-23 | Xerox Corporation | Method and system for measuring the temperature of a thermochromic liquid crystal |
Also Published As
Publication number | Publication date |
---|---|
EP3187594A1 (en) | 2017-07-05 |
US20170191107A1 (en) | 2017-07-06 |
JP2017118872A (en) | 2017-07-06 |
US9963732B2 (en) | 2018-05-08 |
US20200354765A1 (en) | 2020-11-12 |
US11718867B2 (en) | 2023-08-08 |
US20180237820A1 (en) | 2018-08-23 |
EP3187594B1 (en) | 2019-07-10 |
JP6761751B2 (en) | 2020-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11655443B2 (en) | Thermochromic sensing devices, systems, and methods | |
US11718867B2 (en) | Thermochromic sensing devices, systems, and methods | |
JP6050546B2 (en) | Microplate reader with culture device | |
US8173438B1 (en) | Microbiological assessment method and device utilizing oxygen gradient sensing | |
ES2703694T3 (en) | Apparatus for the realization of optical measurements in blood culture bottles | |
US6025189A (en) | Apparatus for reading a plurality of biological indicators | |
US5366873A (en) | Device and method for use in detecting microorganisms in a sample | |
ES2089009T5 (en) | APPARATUS AND METHODS TO TEST ANTIMICROBIAL SUSCEPTIBILITY OF MICROORGANISMS. | |
JP2018503842A (en) | Laser scatter measurement instrument with rotating horse fluid sample configuration | |
ES2443341T3 (en) | Combination of a reading device and an incubator | |
JP2018510333A (en) | System, device and method using integrating sphere concentrator | |
KR20100058514A (en) | Rapid assessment of upper respiratory conditions | |
Yang et al. | Label‐free bacterial colony detection and viability assessment by continuous‐wave terahertz transmission imaging | |
ES2773434T3 (en) | Procedure for detecting the presence or absence of biological particles | |
US20140004558A1 (en) | Detection of Microorganisms With a Fluorescence-Based Device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: XEROX CORPORATION, CONNECTICUT Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PALO ALTO RESEARCH CENTER INCORPORATED;REEL/FRAME:064038/0001 Effective date: 20230416 |
|
AS | Assignment |
Owner name: CITIBANK, N.A., AS COLLATERAL AGENT, NEW YORK Free format text: SECURITY INTEREST;ASSIGNOR:XEROX CORPORATION;REEL/FRAME:064760/0389 Effective date: 20230621 |
|
AS | Assignment |
Owner name: XEROX CORPORATION, CONNECTICUT Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE REMOVAL OF US PATENTS 9356603, 10026651, 10626048 AND INCLUSION OF US PATENT 7167871 PREVIOUSLY RECORDED ON REEL 064038 FRAME 0001. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:PALO ALTO RESEARCH CENTER INCORPORATED;REEL/FRAME:064161/0001 Effective date: 20230416 |
|
AS | Assignment |
Owner name: JEFFERIES FINANCE LLC, AS COLLATERAL AGENT, NEW YORK Free format text: SECURITY INTEREST;ASSIGNOR:XEROX CORPORATION;REEL/FRAME:065628/0019 Effective date: 20231117 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |
|
AS | Assignment |
Owner name: XEROX CORPORATION, CONNECTICUT Free format text: TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT RF 064760/0389;ASSIGNOR:CITIBANK, N.A., AS COLLATERAL AGENT;REEL/FRAME:068261/0001 Effective date: 20240206 Owner name: CITIBANK, N.A., AS COLLATERAL AGENT, NEW YORK Free format text: SECURITY INTEREST;ASSIGNOR:XEROX CORPORATION;REEL/FRAME:066741/0001 Effective date: 20240206 |